Target Name: GPLD1
NCBI ID: G2822
Review Report on GPLD1 Target / Biomarker Content of Review Report on GPLD1 Target / Biomarker
GPLD1
Other Name(s): Phosphatidylinositol-glycan-specific phospholipase D | PIGPLD | glycosylphosphatidylinositol specific phospholipase D1 | Glycosylphosphatidylinositol specific phospholipase D1 | GPI-specific phospholipase D | GPIPLD | PIGPLD1 | PLD | PHLD_HUMAN | Glycoprotein phospholipase D | Glycosyl-phosphatidylinositol-specific phospholipase D | MGC22590 | GPIPLDM | PI-G PLD | glycoprotein phospholipase D | GPI-PLD

Targeting GPLD1 for Drug Development

GPLD1 (Phosphatidylinositol-glycan-specific phospholipase D) is a protein that is expressed in various cell types, including neurons, and is involved in the intracellular signaling pathway known as the phosphatidylcholine (PC) signaling pathway. This pathway is crucial for the regulation of various cellular processes, including cell signaling, protein synthesis, and intracellular transport. Mutations in the GPLD1 gene have been linked to various neurological and psychiatric disorders, making it an attractive target for drug development.

GPLD1 function

GPLD1 is a 26kDa protein that is involved in the PC signaling pathway. The PC signaling pathway is a complex process that involves the interaction between various signaling molecules, including GPLD1. GPLD1 functions as a critical enzyme in the PC signaling pathway by catalyzing the conversion of phosphatidylinositol (PIP) to phosphatidylcholine (PC).

PC is a crucial signaling molecule that is involved in various cellular processes, including cell signaling, protein synthesis, and intracellular transport. It is a key component of the cell membrane and is involved in the regulation of various cellular processes, including the regulation of cell signaling, protein synthesis, and intracellular transport.

GPLD1 is involved in the regulation of PC signaling by catalyzing the conversion of PIP to PC. This conversion is critical for the regulation of various cellular processes, including the regulation of cell signaling, protein synthesis, and intracellular transport.

Drug targeting GPLD1

GPLD1 is a drug target that has been identified as a potential therapeutic target for various neurological and psychiatric disorders. Studies have shown that GPLD1 mutations are associated with the development of various neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and depression.

One of the reasons for the potential targeting of GPLD1 is its involvement in the PC signaling pathway. By targeting GPLD1, researchers can potentially disrupt the regulation of PC signaling and interfere with the regulation of various cellular processes. This, in turn, can lead to the development of various neurological and psychiatric disorders.

Another potential mechanism for targeting GPLD1 is its role in the regulation of intracellular signaling pathways. GPLD1 has been shown to be involved in the regulation of various intracellular signaling pathways, including the regulation of cell signaling, protein synthesis, and intracellular transport. By targeting GPLD1 , researchers can potentially disrupt these pathways and interfere with the regulation of cellular processes.

GPLD1 targeting in drug development

GPLD1 is an attractive target for drug development due to its involvement in the PC signaling pathway and its potential role in the regulation of intracellular signaling pathways. Researchers have developed various methods for targeting GPLD1, including genetic modification, gene editing, and small molecule inhibition.

One of the most promising methods for targeting GPLD1 is small molecule inhibition. Researchers have developed various small molecules that can inhibit the activity of GPLD1 and disrupt its function in the PC signaling pathway. These small molecules have been shown to be effective in animal models of Various neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and depression.

Another method for targeting GPLD1 is gene editing. Researchers have used CRISPR/Cas9 technology to edit the GPLD1 gene and create mutations that are associated with the development of various neurological and psychiatric disorders. These mutations have been shown to be effective in animal models of these disorders and may be useful for drug development.

Conclusion

GPLD1 is a protein that is involved in the PC signaling pathway and has been linked to the development of various neurological and psychiatric disorders. As a result, GPLD1 is an attractive target for drug development and has been the focus of extensive research in the field. Studies have shown that GPLD1 mutations are associated with the development of various disorders, including Alzheimer's disease, Parkinson's disease, and depression. Additionally, GPLD1 has been shown to be involved in the regulation of various intracellular signaling pathways and may play a role in the regulation of cellular processes. Further research is needed to fully understand the role of GPLD1 in the development of these disorders and to develop effective treatments.

Protein Name: Glycosylphosphatidylinositol Specific Phospholipase D1

Functions: This protein hydrolyzes the inositol phosphate linkage in proteins anchored by phosphatidylinositol glycans (GPI-anchor) thus releasing these proteins from the membrane

The "GPLD1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GPLD1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

GPM6A | GPM6B | GPN1 | GPN2 | GPN3 | GPNMB | GPR101 | GPR107 | GPR108 | GPR119 | GPR12 | GPR132 | GPR135 | GPR137 | GPR137B | GPR137C | GPR139 | GPR141 | GPR142 | GPR143 | GPR146 | GPR148 | GPR149 | GPR15 | GPR150 | GPR151 | GPR152 | GPR153 | GPR155 | GPR156 | GPR157 | GPR158 | GPR158-AS1 | GPR15LG | GPR160 | GPR161 | GPR162 | GPR17 | GPR171 | GPR173 | GPR174 | GPR176 | GPR179 | GPR18 | GPR180 | GPR182 | GPR183 | GPR19 | GPR199P | GPR20 | GPR21 | GPR22 | GPR25 | GPR26 | GPR27 | GPR3 | GPR31 | GPR32 | GPR33 | GPR34 | GPR35 | GPR37 | GPR37L1 | GPR39 | GPR4 | GPR42 | GPR45 | GPR50 | GPR52 | GPR55 | GPR6 | GPR61 | GPR62 | GPR63 | GPR65 | GPR68 | GPR75 | GPR75-ASB3 | GPR78 | GPR79 | GPR82 | GPR83 | GPR84 | GPR84-AS1 | GPR85 | GPR87 | GPR88 | GPR89A | GPR89B | GPRACR | GPRASP1 | GPRASP2 | GPRASP3 | GPRC5A | GPRC5B | GPRC5C | GPRC5D | GPRC5D-AS1 | GPRC6A | GPRIN1